Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).

Comprehensive Epilepsy, New York University Medical Center, New York, NY 10016, USA.
Journal of Neural Transmission (Impact Factor: 2.87). 11/2004; 111(10-11):1333-41. DOI: 10.1007/s00702-004-0145-8
Source: PubMed

ABSTRACT Although improved cognition has been reported in patients with mild Parkinson's disease (PD) following the administration of levodopa, mixed results have been found in moderately-to-severely affected PD patients (MSPD), particularly in studies conducted since 1980. In the present study, 16 MSPD patients were tested on separate days, once following overnight levodopa withdrawal and once while optimally treated. A battery of neuropsychological tests that assess a range of cognitive functions (i.e., attention, language, visuospatial, memory, and executive), as well as a measure of depression, were used. Although patients performed better on a measure of confrontation naming in the untreated than in the treated condition, there were no significant differences for any of the other cognitive variables or for the depression scale variable. Thus, these data suggest that there are generally no adverse or beneficial effects of levodopa therapy on cognition in MSPD patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with Parkinson's disease (PD) have deficits in perceptual timing, or the perception and estimation of time. PD patients can also have cognitive symptoms, including deficits in executive functions such as working memory, planning, and visuospatial attention. Here, we discuss how PD-related cognitive symptoms contribute to timing deficits. Timing is influenced by signaling of the neurotransmitter dopamine in the striatum. Timing also involves the frontal cortex, which is dysfunctional in PD. Frontal cortex impairments in PD may influence memory subsystems as well as decision processes during timing tasks. These data suggest that timing may be a type of executive function. As such, timing can be used to study the neural circuitry of cognitive symptoms of PD as they can be studied in animal models. Performance of timing tasks also maybe a useful clinical biomarker of frontal as well as striatal dysfunction in PD.
    Frontiers in Integrative Neuroscience 10/2013; 7:75. DOI:10.3389/fnint.2013.00075
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Idiopathic Parkinson's disease (IPD) is characterized by the clinical motor symptoms of hypokinesia, rigidity, and tremor. Apart from these motor symptoms, cognitive deficits often occur in IPD. The positive effect of cholinesterase inhibitors on cognitive deficits in IPD and findings of earlier molecular imaging studies suggest that the cholinergic system plays an important role in the origin of cognitive decline in IPD.Methods Twenty-five non-demented patients with IPD underwent a 5-[123I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-85380) SPECT to visualize α4β2 nicotinic acetylcholine receptors (nAchR) and cognitive testing with the CERAD (Consortium to Establish a Registry for Alzheimer's Disease) battery to identify domains of cognitive dysfunction.ResultsIn the CERAD, the IPD patients exhibited deficits in non-verbal memory, attention, psychomotor velocity, visuoconstructive ability, and executive functions. After Bonferroni correction for multiple comparisons, we found significant correlations between performance of the CERAD subtests Boston Naming Test (a specific test for visual perception and for detection of word-finding difficulties) and Word List Intrusions (a specific test for learning capacity and memory for language information) vs binding of α4β2 nAchR in cortical (the right superior parietal lobule) and subcortical areas (the left thalamus, the left posterior subcortical region, and the right posterior subcortical region).Conclusions These significant correlations between the results of the CERAD subtests and the cerebral α4β2 nAchR density, as assessed by 5-I-A-85380 SPECT, indicate that cerebral cholinergic pathways are relevant to cognitive processing in IPD.
    Acta Neurologica Scandinavica 04/2014; DOI:10.1111/ane.12259 · 2.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Anomia is often one of the earliest signs of Alzheimer disease (AD), and progressive language impairment remains a major source of disability throughout the disease course.Aims: This article reviews the potential uses of pharmacological adjuvants to augment neuroplasticity during speech and language therapy.Main Contribution: We begin with a discussion of the nature of anomia in AD from the perspective of classical aphasia models and in terms of a parallel distributed processing model of language. Physiological functions of acetylcholine, norepinephrine and dopamine are reviewed. We consider how pharmacological manipulation of these neurotransmitters in combination with speech and language therapy has the potential to promote maintenance and restoration of the functional connectivity within the lexical, semantic and phonological networks that are the basis of propositional language.Conclusions: AD is a disease of synaptic loss. People with AD are able to reacquire knowledge, and pharmacological modulation of acetylcholine, norepinephrine and dopamine can influence the maintenance and reformation of neuronal networks.
    Aphasiology 12/2013; 28(2):219-235. DOI:10.1080/02687038.2013.793283 · 1.73 Impact Factor